Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia

Chin Cheng, Hsien-Jane Chiu, El-Wui Loh, Chin-Hong Chan, Tzong-Ming Hwu, Yun-Ru Liu, Tsuo-Hung Lan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Patients with schizophrenia have a higher risk of developing metabolic abnormalities and their associated diseases. Some studies found that the accumulative number of metabolic syndrome components was associated with the severity of metabolic abnormalities. The purpose of this study was to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in the risk of having more severe metabolic abnormalities among patients with schizophrenia. We studied a sample of 232 chronic inpatients with schizophrenia (120 males and 112 females) to explore the associations between the four candidate genes and the severity of metabolic syndrome by accumulative number of the components. Four single nucleotide polymorphisms in the candidate genes were genotyped, including the Arg347Cys in ADRA1A, the C1291G in ADRA2A, the Try64Arg in ADRB3, and the T102C in 5HT2A. An association between the accumulative number of metabolic syndrome components and the ADRA1A gene was found after adjusting age, sex, and other related variables (p-value = 0.036). Presence of the Arg347 allele in the ADRA1A gene is a risk factor for having more severe metabolic abnormalities. These findings suggest a medical attention of closely monitoring metabolic risks for schizophrenia patients with high-risk genotypes. © 2011 Elsevier Inc.
Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume36
Issue number1
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Schizophrenia
Genes
Gene Components
Single Nucleotide Polymorphism
Inpatients
Alleles
Genotype

Keywords

  • ADRA1A gene
  • ADRA2A gene
  • ADRB3 gene
  • Metabolic syndrome
  • Schizophrenia
  • high density lipoprotein cholesterol
  • neuroleptic agent
  • triacylglycerol
  • 5HT2A gene
  • adult
  • article
  • blood pressure measurement
  • body mass
  • cardiovascular risk
  • cholesterol blood level
  • controlled study
  • disease severity
  • female
  • gene
  • gene frequency
  • gene function
  • genetic analysis
  • genetic association
  • genotype
  • glucose blood level
  • heterozygosity
  • homozygosity
  • human
  • major clinical study
  • male
  • metabolic syndrome X
  • patient monitoring
  • prevalence
  • schizophrenia
  • single nucleotide polymorphism
  • triacylglycerol blood level
  • waist circumference
  • Adult
  • Arginine
  • Cysteine
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Humans
  • Male
  • Metabolic Syndrome X
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Receptors, Adrenergic, alpha-1
  • Risk Factors
  • Severity of Illness Index

Cite this

Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. / Cheng, Chin; Chiu, Hsien-Jane; Loh, El-Wui; Chan, Chin-Hong; Hwu, Tzong-Ming; Liu, Yun-Ru; Lan, Tsuo-Hung.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 36, No. 1, 2012, p. 205-210.

Research output: Contribution to journalArticle

Cheng, Chin ; Chiu, Hsien-Jane ; Loh, El-Wui ; Chan, Chin-Hong ; Hwu, Tzong-Ming ; Liu, Yun-Ru ; Lan, Tsuo-Hung. / Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 ; Vol. 36, No. 1. pp. 205-210.
@article{5461caa7b3344b52b1b054486cdb56d3,
title = "Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia",
abstract = "Patients with schizophrenia have a higher risk of developing metabolic abnormalities and their associated diseases. Some studies found that the accumulative number of metabolic syndrome components was associated with the severity of metabolic abnormalities. The purpose of this study was to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in the risk of having more severe metabolic abnormalities among patients with schizophrenia. We studied a sample of 232 chronic inpatients with schizophrenia (120 males and 112 females) to explore the associations between the four candidate genes and the severity of metabolic syndrome by accumulative number of the components. Four single nucleotide polymorphisms in the candidate genes were genotyped, including the Arg347Cys in ADRA1A, the C1291G in ADRA2A, the Try64Arg in ADRB3, and the T102C in 5HT2A. An association between the accumulative number of metabolic syndrome components and the ADRA1A gene was found after adjusting age, sex, and other related variables (p-value = 0.036). Presence of the Arg347 allele in the ADRA1A gene is a risk factor for having more severe metabolic abnormalities. These findings suggest a medical attention of closely monitoring metabolic risks for schizophrenia patients with high-risk genotypes. {\circledC} 2011 Elsevier Inc.",
keywords = "ADRA1A gene, ADRA2A gene, ADRB3 gene, Metabolic syndrome, Schizophrenia, high density lipoprotein cholesterol, neuroleptic agent, triacylglycerol, 5HT2A gene, adult, article, blood pressure measurement, body mass, cardiovascular risk, cholesterol blood level, controlled study, disease severity, female, gene, gene frequency, gene function, genetic analysis, genetic association, genotype, glucose blood level, heterozygosity, homozygosity, human, major clinical study, male, metabolic syndrome X, patient monitoring, prevalence, schizophrenia, single nucleotide polymorphism, triacylglycerol blood level, waist circumference, Adult, Arginine, Cysteine, Female, Gene Frequency, Genetic Association Studies, Humans, Male, Metabolic Syndrome X, Middle Aged, Polymorphism, Single Nucleotide, Receptors, Adrenergic, alpha-1, Risk Factors, Severity of Illness Index",
author = "Chin Cheng and Hsien-Jane Chiu and El-Wui Loh and Chin-Hong Chan and Tzong-Ming Hwu and Yun-Ru Liu and Tsuo-Hung Lan",
note = "被引用次數:7 Export Date: 29 March 2016 CODEN: PNPPD 通訊地址: Cheng, C.; Department of Psychiatry, Faculty of Medicine, National Yang-Ming University, No. 155, Sec.2, Linong Street, Taipei, 112, Taiwan; 電子郵件: ccchinnn@gmail.com 化學物質/CAS: ADRA1A protein, human; Arginine, 74-79-3; Cysteine, 52-90-4; Receptors, Adrenergic, alpha-1 參考文獻: Alberti, K.G., Zimmet, P., Shaw, J., The metabolic syndrome-a new worldwide definition (2005) Lancet, 366, pp. 1059-1062; Arii, K., Suehiro, T., Yamamoto, M., Ito, H., Ikeda, Y., Nakauchi, Y., Trp64Arg mutation of beta 3-adrenergic receptor and insulin sensitivity in subjects with glucose intolerance (1997) Internal Medicine, 36, pp. 603-606; Basile, V.S., Masellis, M., McIntyre, R.S., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L., Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle (2001) The Journal of Clinical Psychiatry, 62 (SUPPL. 23), pp. 45-66; Bayturan, O., Tuzcu, E.M., Lavoie, A., Hu, T., Wolski, K., Schoenhagen, P., The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis (2010) Archives of Internal Medicine, 170, pp. 478-484; Bolonna, A.A., Arranz, M.J., Munro, J., Osborne, S., Petouni, M., Martinez, M., No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response (2000) Neuroscience Letters, 280, pp. 65-68; Clark, D.A., Arranz, M.J., Mata, I., Lopez-Ilundain, J., Perez-Nievas, F., Kerwin, R.W., Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population (2005) Biological Psychiatry, 58, pp. 435-439; Einhorn, D., Reaven, G.M., Cobin, R.H., Ford, E., Ganda, O.P., Handelsman, Y., American College of Endocrinology position statement on the insulin resistance syndrome (2003) Endocrine Practice, 9, pp. 237-252; Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study (2004) Atherosclerosis, 173, pp. 309-314; Ford, E.S., Giles, W.H., Dietz, W.H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey (2002) JAMA: The Journal of the American Medical Association, 287, pp. 356-359; Freitas, S.R., Pereira, A.C., Floriano, M.S., Mill, J.G., Krieger, J.E., Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population (2008) BMC Cardiovascular Disorders, 8, p. 40; Gerstein, H.C., Anand, S., Yi, Q.L., Vuksan, V., Lonn, E., Teo, K., The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study (2003) Diabetes Care, 26, pp. 144-149; Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C., Lenfant, C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition (2004) Circulation, 109, pp. 433-438; Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) Circulation, 112, pp. 2735-2752; Gu, D., Ge, D., Snieder, H., He, J., Chen, S., Huang, J., Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension (2006) Journal of Hypertension, 24, pp. 1049-1056; Gunes, A., Melkersson, K.I., Scordo, M.G., Dahl, M.L., Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (2009) Journal of Clinical Psychopharmacology, 29, pp. 65-68; Huang, K., Shi, Y., Tang, W., Tang, R., Guo, S., Xu, Y., No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population (2008) Journal of Psychiatric Research, 42, pp. 384-388; Huang, Y., Zhao, Z., Li, X., Wang, J., Xu, M., Bi, Y., Prevalence of metabolic syndrome and its association with obesity indices in a Chinese population (2009) Journal of Diabetes, 1, pp. 57-64; Hwang, L.C., Bai, C.H., Chen, C.J., Prevalence of obesity and metabolic syndrome in Taiwan (2006) Journal of the Formosan Medical Association, 105, pp. 626-635; Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men (2002) JAMA: The Journal of the American Medical Association, 288, pp. 2709-2716; Liu, Y.R., Loh, E.W., Lan, T.H., Chen, S.F., Yu, Y.H., Chang, Y.H., ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics (2010) The Pharmacogenomics Journal, 10, pp. 30-39; Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Physical health monitoring of patients with schizophrenia (2004) The American Journal of Psychiatry, 161, pp. 1334-1349; Masuo, K., Katsuya, T., Fu, Y., Rakugi, H., Ogihara, T., Tuck, M.L., Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years (2005) Circulation, 111, pp. 3429-3434; Matsushita, Y., Yokoyama, T., Yoshiike, N., Matsumura, Y., Date, C., Kawahara, K., The Trp(64)Arg polymorphism of the beta(3)-adrenergic receptor gene is not associated with body weight or body mass index in Japanese: a longitudinal analysis (2003) Journal of Clinical Endocrinology and Metabolism, 88, pp. 5914-5920; Mozaffarian, D., Kamineni, A., Prineas, R.J., Siscovick, D.S., Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study (2008) Archives of Internal Medicine, 168, pp. 969-978; Ochoa, M.C., Marti, A., Azcona, C., Chueca, M., Oyarzabal, M., Pelach, R., Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents (2004) International Journal of Obesity and Related Metabolic Disorders, 28 (SUPPL. 3), pp. S37-S41; Park, Y.M., Chung, Y.C., Lee, S.H., Lee, K.J., Kim, H., Byun, Y.C., Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment (2006) American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 141 B, pp. 394-397; Phares, D.A., Halverstadt, A.A., Shuldiner, A.R., Ferrell, R.E., Douglass, L.W., Ryan, A.S., Association between body fat response to exercise training and multilocus ADR genotypes (2004) Obesity Research, 12, pp. 807-815; Piascik, M.T., Perez, D.M., Alpha1-adrenergic receptors: new insights and directions (2001) Journal of Pharmacology and Experimental Therapeutics, 298, pp. 403-410; Rodriguez-Colon, S.M., Mo, J., Duan, Y., Liu, J., Caulfield, J.E., Jin, X., Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study (2009) Stroke, 40, pp. 200-205; Ross, R., Despres, J.P., Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise (2009) Obesity (Silver Spring), 17 (SUPPL. 3), pp. S1-S2; Ryan, M.C., Thakore, J.H., Physical consequences of schizophrenia and its treatment: the metabolic syndrome (2002) Life Sciences, 71, pp. 239-257; Sakane, N., Yoshida, T., Umekawa, T., Kogure, A., Takakura, Y., Kondo, M., Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients (1997) Diabetes Care, 20, pp. 1887-1890; Sattar, N., McConnachie, A., Shaper, A.G., Blauw, G.J., Buckley, B.M., de Craen, A.J., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) Lancet, 371, pp. 1927-1935; Sickert, L., Muller, D.J., Tiwari, A.K., Shaikh, S., Zai, C., De Souza, R., Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans (2009) Pharmacogenomics, 10, pp. 1169-1176; Silverstein, S.M., Spaulding, W.D., Menditto, A.A., Savitz, A., Liberman, R.P., Berten, S., Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia (2009) Schizophrenia Bulletin, 35, pp. 222-232; Sofowora, G.G., Dishy, V., Landau, R., Xie, H.G., Prasad, H.C., Byrne, D.W., Alpha 1A-adrenergic receptor polymorphism and vascular response (2004) Clinical Pharmacology and Therapeutics, 75, pp. 539-545; Suvisaari, J.M., Saarni, S.I., Perala, J., Suvisaari, J.V., Harkanen, T., Lonnqvist, J., Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey (2007) The Journal of Clinical Psychiatry, 68, pp. 1045-1055; Thakore, J.H., Metabolic syndrome and schizophrenia (2005) The British Journal of Psychiatry, 186, pp. 455-456; Tsai, P.J., Ho, S.C., Tsai, L.P., Lee, Y.H., Hsu, S.P., Yang, S.P., Lack of relationship between beta3-adrenergic receptor gene polymorphism and gestational diabetes mellitus in a Taiwanese population (2004) Metabolism, 53, pp. 1136-1139; Ujike, H., Nomura, A., Morita, Y., Morio, A., Okahisa, Y., Kotaka, T., Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study (2008) The Journal of Clinical Psychiatry, 69, pp. 1416-1422; Vancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia (2010) Psychiatry Research, 177, pp. 271-279; Walston, J., Silver, K., Bogardus, C., Knowler, W.C., Celi, F.S., Austin, S., Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene (1995) The New England Journal of Medicine, 333, pp. 343-347; Wang, Y.C., Bai, Y.M., Chen, J.Y., Lin, C.C., Lai, I.C., Liou, Y.J., Polymorphism of the adrenergic receptor alpha 2a-1291C>G genetic variation and clozapine-induced weight gain (2005) Journal of Neural Transmission, 112, pp. 1463-1468; Wang, J.J., Li, H.B., Kinnunen, L., Hu, G., Jarvinen, T.M., Miettinen, M.E., How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population? (2007) Atherosclerosis, 192, pp. 161-168; Zhang, Y., Hong, X., Liu, H., Huo, Y., Xu, X., Arg347Cys polymorphism of alpha1A-adrenoceptor gene is associated with blood pressure response to nifedipine GITS in Chinese hypertensive patients (2009) Journal of Human Genetics, 54, pp. 360-364",
year = "2012",
doi = "10.1016/j.pnpbp.2011.10.011",
language = "English",
volume = "36",
pages = "205--210",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia

AU - Cheng, Chin

AU - Chiu, Hsien-Jane

AU - Loh, El-Wui

AU - Chan, Chin-Hong

AU - Hwu, Tzong-Ming

AU - Liu, Yun-Ru

AU - Lan, Tsuo-Hung

N1 - 被引用次數:7 Export Date: 29 March 2016 CODEN: PNPPD 通訊地址: Cheng, C.; Department of Psychiatry, Faculty of Medicine, National Yang-Ming University, No. 155, Sec.2, Linong Street, Taipei, 112, Taiwan; 電子郵件: ccchinnn@gmail.com 化學物質/CAS: ADRA1A protein, human; Arginine, 74-79-3; Cysteine, 52-90-4; Receptors, Adrenergic, alpha-1 參考文獻: Alberti, K.G., Zimmet, P., Shaw, J., The metabolic syndrome-a new worldwide definition (2005) Lancet, 366, pp. 1059-1062; Arii, K., Suehiro, T., Yamamoto, M., Ito, H., Ikeda, Y., Nakauchi, Y., Trp64Arg mutation of beta 3-adrenergic receptor and insulin sensitivity in subjects with glucose intolerance (1997) Internal Medicine, 36, pp. 603-606; Basile, V.S., Masellis, M., McIntyre, R.S., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L., Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle (2001) The Journal of Clinical Psychiatry, 62 (SUPPL. 23), pp. 45-66; Bayturan, O., Tuzcu, E.M., Lavoie, A., Hu, T., Wolski, K., Schoenhagen, P., The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis (2010) Archives of Internal Medicine, 170, pp. 478-484; Bolonna, A.A., Arranz, M.J., Munro, J., Osborne, S., Petouni, M., Martinez, M., No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response (2000) Neuroscience Letters, 280, pp. 65-68; Clark, D.A., Arranz, M.J., Mata, I., Lopez-Ilundain, J., Perez-Nievas, F., Kerwin, R.W., Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population (2005) Biological Psychiatry, 58, pp. 435-439; Einhorn, D., Reaven, G.M., Cobin, R.H., Ford, E., Ganda, O.P., Handelsman, Y., American College of Endocrinology position statement on the insulin resistance syndrome (2003) Endocrine Practice, 9, pp. 237-252; Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study (2004) Atherosclerosis, 173, pp. 309-314; Ford, E.S., Giles, W.H., Dietz, W.H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey (2002) JAMA: The Journal of the American Medical Association, 287, pp. 356-359; Freitas, S.R., Pereira, A.C., Floriano, M.S., Mill, J.G., Krieger, J.E., Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population (2008) BMC Cardiovascular Disorders, 8, p. 40; Gerstein, H.C., Anand, S., Yi, Q.L., Vuksan, V., Lonn, E., Teo, K., The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study (2003) Diabetes Care, 26, pp. 144-149; Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C., Lenfant, C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition (2004) Circulation, 109, pp. 433-438; Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) Circulation, 112, pp. 2735-2752; Gu, D., Ge, D., Snieder, H., He, J., Chen, S., Huang, J., Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension (2006) Journal of Hypertension, 24, pp. 1049-1056; Gunes, A., Melkersson, K.I., Scordo, M.G., Dahl, M.L., Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (2009) Journal of Clinical Psychopharmacology, 29, pp. 65-68; Huang, K., Shi, Y., Tang, W., Tang, R., Guo, S., Xu, Y., No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population (2008) Journal of Psychiatric Research, 42, pp. 384-388; Huang, Y., Zhao, Z., Li, X., Wang, J., Xu, M., Bi, Y., Prevalence of metabolic syndrome and its association with obesity indices in a Chinese population (2009) Journal of Diabetes, 1, pp. 57-64; Hwang, L.C., Bai, C.H., Chen, C.J., Prevalence of obesity and metabolic syndrome in Taiwan (2006) Journal of the Formosan Medical Association, 105, pp. 626-635; Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men (2002) JAMA: The Journal of the American Medical Association, 288, pp. 2709-2716; Liu, Y.R., Loh, E.W., Lan, T.H., Chen, S.F., Yu, Y.H., Chang, Y.H., ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics (2010) The Pharmacogenomics Journal, 10, pp. 30-39; Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Physical health monitoring of patients with schizophrenia (2004) The American Journal of Psychiatry, 161, pp. 1334-1349; Masuo, K., Katsuya, T., Fu, Y., Rakugi, H., Ogihara, T., Tuck, M.L., Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years (2005) Circulation, 111, pp. 3429-3434; Matsushita, Y., Yokoyama, T., Yoshiike, N., Matsumura, Y., Date, C., Kawahara, K., The Trp(64)Arg polymorphism of the beta(3)-adrenergic receptor gene is not associated with body weight or body mass index in Japanese: a longitudinal analysis (2003) Journal of Clinical Endocrinology and Metabolism, 88, pp. 5914-5920; Mozaffarian, D., Kamineni, A., Prineas, R.J., Siscovick, D.S., Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study (2008) Archives of Internal Medicine, 168, pp. 969-978; Ochoa, M.C., Marti, A., Azcona, C., Chueca, M., Oyarzabal, M., Pelach, R., Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents (2004) International Journal of Obesity and Related Metabolic Disorders, 28 (SUPPL. 3), pp. S37-S41; Park, Y.M., Chung, Y.C., Lee, S.H., Lee, K.J., Kim, H., Byun, Y.C., Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment (2006) American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 141 B, pp. 394-397; Phares, D.A., Halverstadt, A.A., Shuldiner, A.R., Ferrell, R.E., Douglass, L.W., Ryan, A.S., Association between body fat response to exercise training and multilocus ADR genotypes (2004) Obesity Research, 12, pp. 807-815; Piascik, M.T., Perez, D.M., Alpha1-adrenergic receptors: new insights and directions (2001) Journal of Pharmacology and Experimental Therapeutics, 298, pp. 403-410; Rodriguez-Colon, S.M., Mo, J., Duan, Y., Liu, J., Caulfield, J.E., Jin, X., Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study (2009) Stroke, 40, pp. 200-205; Ross, R., Despres, J.P., Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise (2009) Obesity (Silver Spring), 17 (SUPPL. 3), pp. S1-S2; Ryan, M.C., Thakore, J.H., Physical consequences of schizophrenia and its treatment: the metabolic syndrome (2002) Life Sciences, 71, pp. 239-257; Sakane, N., Yoshida, T., Umekawa, T., Kogure, A., Takakura, Y., Kondo, M., Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients (1997) Diabetes Care, 20, pp. 1887-1890; Sattar, N., McConnachie, A., Shaper, A.G., Blauw, G.J., Buckley, B.M., de Craen, A.J., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) Lancet, 371, pp. 1927-1935; Sickert, L., Muller, D.J., Tiwari, A.K., Shaikh, S., Zai, C., De Souza, R., Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans (2009) Pharmacogenomics, 10, pp. 1169-1176; Silverstein, S.M., Spaulding, W.D., Menditto, A.A., Savitz, A., Liberman, R.P., Berten, S., Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia (2009) Schizophrenia Bulletin, 35, pp. 222-232; Sofowora, G.G., Dishy, V., Landau, R., Xie, H.G., Prasad, H.C., Byrne, D.W., Alpha 1A-adrenergic receptor polymorphism and vascular response (2004) Clinical Pharmacology and Therapeutics, 75, pp. 539-545; Suvisaari, J.M., Saarni, S.I., Perala, J., Suvisaari, J.V., Harkanen, T., Lonnqvist, J., Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey (2007) The Journal of Clinical Psychiatry, 68, pp. 1045-1055; Thakore, J.H., Metabolic syndrome and schizophrenia (2005) The British Journal of Psychiatry, 186, pp. 455-456; Tsai, P.J., Ho, S.C., Tsai, L.P., Lee, Y.H., Hsu, S.P., Yang, S.P., Lack of relationship between beta3-adrenergic receptor gene polymorphism and gestational diabetes mellitus in a Taiwanese population (2004) Metabolism, 53, pp. 1136-1139; Ujike, H., Nomura, A., Morita, Y., Morio, A., Okahisa, Y., Kotaka, T., Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study (2008) The Journal of Clinical Psychiatry, 69, pp. 1416-1422; Vancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia (2010) Psychiatry Research, 177, pp. 271-279; Walston, J., Silver, K., Bogardus, C., Knowler, W.C., Celi, F.S., Austin, S., Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene (1995) The New England Journal of Medicine, 333, pp. 343-347; Wang, Y.C., Bai, Y.M., Chen, J.Y., Lin, C.C., Lai, I.C., Liou, Y.J., Polymorphism of the adrenergic receptor alpha 2a-1291C>G genetic variation and clozapine-induced weight gain (2005) Journal of Neural Transmission, 112, pp. 1463-1468; Wang, J.J., Li, H.B., Kinnunen, L., Hu, G., Jarvinen, T.M., Miettinen, M.E., How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population? (2007) Atherosclerosis, 192, pp. 161-168; Zhang, Y., Hong, X., Liu, H., Huo, Y., Xu, X., Arg347Cys polymorphism of alpha1A-adrenoceptor gene is associated with blood pressure response to nifedipine GITS in Chinese hypertensive patients (2009) Journal of Human Genetics, 54, pp. 360-364

PY - 2012

Y1 - 2012

N2 - Patients with schizophrenia have a higher risk of developing metabolic abnormalities and their associated diseases. Some studies found that the accumulative number of metabolic syndrome components was associated with the severity of metabolic abnormalities. The purpose of this study was to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in the risk of having more severe metabolic abnormalities among patients with schizophrenia. We studied a sample of 232 chronic inpatients with schizophrenia (120 males and 112 females) to explore the associations between the four candidate genes and the severity of metabolic syndrome by accumulative number of the components. Four single nucleotide polymorphisms in the candidate genes were genotyped, including the Arg347Cys in ADRA1A, the C1291G in ADRA2A, the Try64Arg in ADRB3, and the T102C in 5HT2A. An association between the accumulative number of metabolic syndrome components and the ADRA1A gene was found after adjusting age, sex, and other related variables (p-value = 0.036). Presence of the Arg347 allele in the ADRA1A gene is a risk factor for having more severe metabolic abnormalities. These findings suggest a medical attention of closely monitoring metabolic risks for schizophrenia patients with high-risk genotypes. © 2011 Elsevier Inc.

AB - Patients with schizophrenia have a higher risk of developing metabolic abnormalities and their associated diseases. Some studies found that the accumulative number of metabolic syndrome components was associated with the severity of metabolic abnormalities. The purpose of this study was to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in the risk of having more severe metabolic abnormalities among patients with schizophrenia. We studied a sample of 232 chronic inpatients with schizophrenia (120 males and 112 females) to explore the associations between the four candidate genes and the severity of metabolic syndrome by accumulative number of the components. Four single nucleotide polymorphisms in the candidate genes were genotyped, including the Arg347Cys in ADRA1A, the C1291G in ADRA2A, the Try64Arg in ADRB3, and the T102C in 5HT2A. An association between the accumulative number of metabolic syndrome components and the ADRA1A gene was found after adjusting age, sex, and other related variables (p-value = 0.036). Presence of the Arg347 allele in the ADRA1A gene is a risk factor for having more severe metabolic abnormalities. These findings suggest a medical attention of closely monitoring metabolic risks for schizophrenia patients with high-risk genotypes. © 2011 Elsevier Inc.

KW - ADRA1A gene

KW - ADRA2A gene

KW - ADRB3 gene

KW - Metabolic syndrome

KW - Schizophrenia

KW - high density lipoprotein cholesterol

KW - neuroleptic agent

KW - triacylglycerol

KW - 5HT2A gene

KW - adult

KW - article

KW - blood pressure measurement

KW - body mass

KW - cardiovascular risk

KW - cholesterol blood level

KW - controlled study

KW - disease severity

KW - female

KW - gene

KW - gene frequency

KW - gene function

KW - genetic analysis

KW - genetic association

KW - genotype

KW - glucose blood level

KW - heterozygosity

KW - homozygosity

KW - human

KW - major clinical study

KW - male

KW - metabolic syndrome X

KW - patient monitoring

KW - prevalence

KW - schizophrenia

KW - single nucleotide polymorphism

KW - triacylglycerol blood level

KW - waist circumference

KW - Adult

KW - Arginine

KW - Cysteine

KW - Female

KW - Gene Frequency

KW - Genetic Association Studies

KW - Humans

KW - Male

KW - Metabolic Syndrome X

KW - Middle Aged

KW - Polymorphism, Single Nucleotide

KW - Receptors, Adrenergic, alpha-1

KW - Risk Factors

KW - Severity of Illness Index

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-82555176502&origin=inward&txGid=c28b303ce9413296cdd534db2d8cd951

UR - https://www.scopus.com/results/citedbyresults.uri?sort=plf-f&cite=2-s2.0-82555176502&src=s&imp=t&sid=7e344e2378aa9bba5197d4b41016f29b&sot=cite&sdt=a&sl=0&origin=recordpage&editSaveSearch=&txGid=98a2c4300bfc59b3b3dc6d3bf14f5fd7

U2 - 10.1016/j.pnpbp.2011.10.011

DO - 10.1016/j.pnpbp.2011.10.011

M3 - Article

VL - 36

SP - 205

EP - 210

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -